Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 6/20 | 0.43 |
| ▸ | SSTR1 | P30872 | 2/20 | 0.43 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.43 |
| ▸ | HPGDS | O60760 | 8/20 | 0.43 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.36 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.35 |
| ▸ | PTGES | O14684 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21222302 | 1.00 | EPHX2 (0.43) | EPHX2SSTR1SSTR4HPGDSACKR3 | |
| SCHEMBL21222050 | 0.88 | HPGDS (0.44) | EPHX2HPGDS | |
| SCHEMBL20064724 | 0.88 | HPGDS (0.44) | EPHX2HPGDS | |
| SCHEMBL20064644 | 0.87 | HPGDS (0.45) | HPGDSS1PR5PTGES | |
| SCHEMBL21221977 | 0.87 | HPGDS (0.45) | HPGDSS1PR5PTGES | |
| SCHEMBL20064617 | 0.86 | PTGES (0.47) | EPHX2SSTR1SSTR4HPGDSPTGES | |
| SCHEMBL21222471 | 0.86 | PTGES (0.47) | EPHX2SSTR1SSTR4HPGDSPTGES | |
| SCHEMBL21228028 | 0.82 | SSTR1 (0.45) | EPHX2SSTR1SSTR4HPGDS | |
| SCHEMBL21221969 | 0.81 | HPGDS (0.43) | EPHX2HPGDSPTGES | |
| SCHEMBL20065720 | 0.81 | HPGDS (0.43) | EPHX2HPGDSPTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190241554-A1 | 1,3 DI-SUBSTITUTED CYCLOBUTANE OR AZETIDINE DERIVATIVES AS HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-08-08 | — | — | US | claimed |
| US-11053234-B2 | 1,3 di-substituted cyclobutane or azetidine derivatives as hematopoietic prostaglandin D synthase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-07-06 | — | — | US | disclosed |
| US-20190241554-A1 | 1,3 DI-SUBSTITUTED CYCLOBUTANE OR AZETIDINE DERIVATIVES AS HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11053234-B2 | 1,3 di-substituted cyclobutane or azetidine derivatives as hematopoietic prostaglandin D synthase inhibitors | HPGDS, PTGDR, PTGER1 | EPHX2 436/4885SSTR1 1921/4885SSTR4 3821/4885 |
| US-20190241554-A1 | 1,3 DI-SUBSTITUTED CYCLOBUTANE OR AZETIDINE DERIVATIVES AS HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE INHIBITORS | HPGDS, PTGDR, PTGER1 | EPHX2 436/4885SSTR1 1921/4885SSTR4 3821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.